Sibutramine--a review of clinical efficacy.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity

• Publication date

  1997-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 9130039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years.

  1995cited by this paper
• Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.

  1994cited by this paper
• Influences on Weight Loss in Type 2 Diabetic Patients: Little Long‐term Benefit from Group Behaviour Therapy and Exercise Training

  1994cited by this paper
• Long‐term weight control study: Conclusions

  1992cited by this paper
• International trial of long-term dexfenfluramine in obesity.

  1989cited by this paper

• Sibutramine high-doses effects in cafeteria diet-induced obese rats.

  2026cites this paper
• Psychopharmacotherapy in eating disorders: a systematic analysis.

  2025cites this paper
• Novel Strategies for Medical Management of Obesity: Mechanisms, Clinical Implications, and Societal Impacts: a report from the 25th annual Harvard Nutrition Obesity Symposium.

  2025cites this paper
• The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics

  2023cites this paper
• Rational Design, Synthesis and Characterization of Novel Sibutramine Derivatives as Anti-Obesity Activity

  2023cites this paper
• Management of obesity

  2023cites this paper
• A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss

  2021cites this paper
• Weight Loss at First Month and Development of Tolerance as Possible Predictors of 30 mg Phentermine Efficacy at 6 Months

  2021cites this paper
• Development and Validation of Sibutramine Determination in Drug Products by Capillary Electrophoresis

  2020cites this paper
• Neuropeptide receptors as potential pharmacological targets for obesity

  2019cites this paper
• Short-Term Evidence in Adults of Anorexigenic Drugs Acting in the Central Nervous System: A Meta-Analysis.

  2019cites this paper
• Efeitos da exposição de ratos machos Wistar adultos a estatinas e inibidores de recaptura de neurotransmissores sobre parâmetros reprodutivos e a fertilidade

  2018cites this paper
• A 40-Year-Old Woman With a Strong Family History of Breast Cancer, 1 Year Later

  2017cites this paper
• Epidemiology of Obesity and Pharmacologic Treatment Options

  2017cites this paper
• Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

  2017cites this paper
• Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles

  2016cites this paper
• Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases

  2014cites this paper
• Kapitel 4 – Erkrankungen des Stoffwechsels∗

  2014cites this paper
• Different Effects of Clopidogrel and Clarithromycin on the Enantioselective Pharmacokinetics of Sibutramine and its Active Metabolites in Healthy Subjects

  2013cites this paper
• The Effect of a 12-week Weight Management Program on the Quality of Life in Patients with Schizophrenia

  2012cites this paper
• OBESITY IN TYPE 2 DIABETES: A REVIEW OF HEALTH ECONOMICS EVIDENCES

  2012cites this paper
• Serotonin Receptor 2A −1438G/A Promoter Polymorphism in Relation to Obesity and Response to Sibutramine

  2012cites this paper
• Obesity and Psychotropics

  2012cites this paper
• Pharmacotherapy for Obesity

  2012cites this paper
• Ventricular Tachycardia Associated with Sibutramine Treatment

  2011cites this paper
• Taquicardia ventricular asociada con la utilización de sibutramina

  2011cites this paper
• Weight Gain, Obesity, and Psychotropic Prescribing

  2011cites this paper
• Efeito da sibutramina na redução do peso e no perfil metabólico em indivíduos obesos de uma população brasileira

  2010cites this paper
• Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment

  2010cites this paper
• Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

  2010cites this paper
• Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

  2009cites this paper
• Treating diabetes and prediabetes by focusing on obesity management

  2009cites this paper
• Double-blind, Randomized, Multi-center, Comparative Clinical Trial of Sibutramine Mesilate with Sibutramine Hydrochloride for Evaluating Efficacy and Safety in Obese Patients

  2008cites this paper
• Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK*

  2008cites this paper
• Sibutramine-induced acute myocardial infarction in a young lady

  2008cites this paper
• The Effect of Sibutramine Intake on Resting and Exercise Physiological Responses

  2008cites this paper
• Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes

  2008cites this paper
• Sibutramine: current status as an anti-obesity drug and its future perspectives

  2008cites this paper
• [Current drug formulations in obesity therapy].

  2008cites this paper
• Management of obesity : Results of SCoUT Trial

  2008cites this paper
• Management of type 2 diabetes in the obese patient: current concerns and emerging therapies

  2008cites this paper
• Genotype-specific weight loss treatment advice: how close are we?

  2007cites this paper
• Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status

  2007cites this paper
• Clinical surgery-American Treating morbid obesity with laparoscopic adjustable gastric banding

  2007cites this paper
• Treating morbid obesity with laparoscopic adjustable gastric banding.

  2007cites this paper
• Tratamiento farmacológico de la obesidad: presente, pasado y futuro

  2007cites this paper
• D4 – Therapie der Adipositas im Kindes- und Jugendalter (S3)1

  2007cites this paper
• Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

  2007cites this paper
• Weight Loss in Obese African American and Caucasian Adolescents: Secondary Analysis of a Randomized Clinical Trial of Behavioral Therapy Plus Sibutramine

  2007cites this paper
• El grado de obesidad modifica la respuesta de disminución de circunferencia de cintura en pacientes que reciben 15 mg diarios de sibutramina. Estudio abierto sobre tolerancia y efectividad de la sibutramina

  2007cites this paper
• [Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally].

  2007cites this paper
• Studies on lipoprotein kinetics in obesity and the metabolic syndrome: impact of dietary weight loss and statin therapy

  2007cites this paper
• Effect of sibutramine on intraocular pressure

  2006cites this paper
• State of the science: VLED (Very Low Energy Diet) for obesity.

  2006cites this paper
• Orlistat and Sibutramine in the Management of Obesity

  2006cites this paper
• Pharmacological and surgical treatments for obesity.

  2006cites this paper
• Neuropharmacology of obstructive sleep apnea and central apnea

  2006cites this paper
• Treatment of obesity: a challenging task.

  2006cites this paper
• Weight management for the obese patient in primary care: is a commercially available weight loss programme the answer?

  2006cites this paper
• Medikamentöse Therapie der Adipositas

  2006cites this paper
• ORIGINAL COMMUNICATION Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo- controlled, parallel group study

  2005cites this paper
• Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study.

  2005cites this paper
• Overview and the Future of Obesity Treatment

  2005cites this paper
• Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study

  2005cites this paper
• Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects

  2005cites this paper
• Behavioral treatment of obesity.

  2005cites this paper
• Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

  2005cites this paper
• Management of nonalcoholic fatty liver disease: weight control.

  2004cites this paper
• Prevention and Treatment of Obesity - An Over View

  2004cites this paper
• Comparison of Efficacy of Sibutramine or Orlistat Versus Their Combination in Obese Women

  2004cites this paper
• Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.

  2004cites this paper
• Pharmacotherapy of obesity.

  2004cites this paper
• Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

  2004cites this paper
• 80 – Weight Reduction Therapies: Anorectants, Thermogenics, and Lipolytics

  2004cites this paper
• Tratamiento de la obesidad. Medidas de estilo de vida y régimen alimentario. Tratamiento farmacológico. Tratamiento quirúrgico

  2004cites this paper
• Psychiatric medication‐induced obesity: treatment options

  2004cites this paper
• Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.

  2003cites this paper
• Behavioral treatment of obesity.

  2003cites this paper
• Obesity and Type-2 Diabetes in the Elderly

  2003cites this paper
• A Benefit-Risk Assessment of Sibutramine in the Management of Obesity

  2003cites this paper
• Step 3 — Know the main psychological blocks to self management

  2003cites this paper
• Obesity: Selected Medical Issues

  2003cites this paper
• Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double‐blind, randomized, placebo‐controlled trial

  2003cites this paper
• Gewichtsreduktion mittels Pharmakotherapie

  2003cites this paper
• Continuing education

  2003cites this paper
• Effects of Sibutramine Assisted Weight Loss on Body Composition, Metabolic Parameters and Insulin Resistance

  2003cites this paper
• Treatment of Obesity: An Overview

  2003cites this paper
• Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.

  2003cites this paper
• Use of sibutramine to treat obesity.

  2003cites this paper
• Management of the overweight patient with Type 2 diabetes

  2003cites this paper
• Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism.

  2003cites this paper
• Pharmacotherapy for dyslipidaemia – current therapies and future agents

  2003cites this paper
• Obesity: responding to the global epidemic.

  2002cites this paper
• Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

  2002cites this paper
• Obesity treatment: factors involved in weight-loss maintenance and regain

  2002cites this paper
• Obesity, Cardiovascular Risk and Pharmacotherapy

  2002cites this paper
• Anti-obesity drug development

  2002cites this paper
• Metabolic imprinting and the obesity epidemic

  2002cites this paper
• The medical benefit of 5-HT research.

  2002cites this paper
• [Weight reduction. Antiobesity drug treatment in type-2 diabetics].

  2002cites this paper